Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Cytarabine
Disease-Free Survival
Double-Blind Method
Female
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute
Male
Middle Aged
Naphthyridines
Neoplasm Recurrence, Local
Remission Induction
Thiazoles
Treatment Outcome

authors with profiles

Olatoyosi Odenike